Activity of EGFR, mTOR and PI3K Inhibitors in an Isogenic Breast Cell Line Model

BMC Research Notes - United Kingdom
doi 10.1186/1756-0500-7-397
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates

Cancer Research
Cancer ResearchOncology
2011English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination With Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

AXL Circumvents PI3K Inhibition by Activating EGFR-PKC-mTOR Signaling

Cancer Discovery
Oncology
2015English

Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

The Impact of PI3K Inhibitors on Breast Cancer Cell and Its Tumor Microenvironment

PeerJ
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgriculturalNeuroscience
2018English

Cell Migration Induced by Native Type IV Collagen Requires PI3K/Akt2 and EGFR Activity in MDA-MB-231 Breast Cancer Cells

Cancer Research Journal
2015English

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Science Signaling
BiochemistryCell BiologyMolecular Biology
2014English

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy